Q-omics provides the consensus-scored ENOX1 profile across patient tissues and cancer cell-line models. ENOX1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, ENOX1 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, ENOX1 RNA expression shows 22,412 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, KIRC, and GBM as cancer lineages where ENOX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ENOX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ENOX1 survival associations across molecular data types. ENOX1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ENOX1 RNA expression–survival associations across cancer types. High ENOX1 expression shows unfavorable associations in LUAD, UVM, ACC, STAD, MESO and UCEC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for ENOX1 RNA expression.
This table summarizes ENOX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ENOX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ENOX1 shows lower tumor expression in KIRC, KICH, KIRP and UCEC and higher tumor expression in HNSC and LIHC. The KIRC box plot shows higher ENOX1 RNA expression in normal versus tumor tissue (log2 FC = −1.549, t-test p < 0.001).
This table shows molecular features associated with ENOX1 in patient tissues and cancer cell lines. In patient samples, ENOX1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ENOX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
